Phase II Combination of Gemcitabine (Fixed Dose-rate Infusion, FDR), Irinotecan and Panitumumab in Patients With Advanced and Metastatic Biliary Tract Adenocarcinoma

Inclusion Criteria:

- histologically or cytologically confirmed local advanced unresectable/metastatic
adenocarcinoma of biliary tract

- measurable disease

- available tumor tissue for investigational immunohistochemical evaluations

- ECOG PS 0-2

- No prior chemotherapy, biologic therapy or radiation therapy

- Age Eighteen and older

- Lab values per protocol

Exclusion Criteria:

- Life expectancy less than three months

- Concurrent use of chemotherapy not indicated in the study protocol or any other
investigational agents and patients who have received investigational drugs less than
four weeks prior to enrollment

- Prior therapy, which affects or targets the EGF pathway

- Treatment for other carcinomas within the last five years, except cured non-melanoma
skin and treated in-situ cervical cancer

- Recovery from major surgery within three weeks of the start of study treatment